BEIJING, Dec. 6, 2010 /PRNewswire-Asia-FirstCall/ — China
Medical Technologies, Inc. (the “Company”) (Nasdaq:
CMED), a leading China-based advanced in-vitro diagnostic
(“IVD”) company, today announced that its wholly-owned
subsidiaries, Beijing GP Medical Technologies Co., Ltd. (“GP
Medical”) and Beijing Yuande Bio-Medical Engineering Co., Ltd.
(“Beijing Yuande”), have been ranked 12th and 415th, respectively,
in the Deloitte Technology Fast 500 Asia Pacific 2010 program. GP
Medical operates the fast growing molecular diagnostic business of
the Company, and Beijing Yuande operates the immunodiagnostic
business of the Company.
“We are honored to be named in the Deloitte Technology Fast 500
Asia Pacific for 2010,” commented Mr. Xiaodong Wu, Chairman and
Chief Executive Officer of the Company. “We believe that there is
good market potential in both molecular diagnostics and
immunodiagnostics in China, and we will continue to focus on
capturing these market opportunities.”
About China Medical Technologies, Inc.China
Medical Technologies, Inc. is a leading China-based advanced IVD
company using molecular diagnostic technologies including
Fluorescent in situ Hybridization (FISH) and Surface Plasmon
Resonance (SPR) and an immunodiagnostic technology, Enhanced
Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and
distribute diagnostic products used for the detection of various
cancers, diseases and disorders as well as companion diagnostic
tests for targeted cancer drugs. The Company generates all of its
revenues in China through the sale of diagnostic consumables
including FISH probes, SPR-based DNA chips and ECLIA reagent kits
to hospitals which are recurring users of the consumables for their
patients. The Company sells FISH probes and SPR chips to large
hospitals through its direct sales force and ECLIA reagent kits to
small and mid-size hosp
‘/>”/>
